WASHINGTON — Although the 30-day period for public comment on the National Institutes of Health’s draft guidelines for funding of embryonic stem-cell research has ended, the U.S. bishops are continuing their campaign urging members of Congress not to permit such funding.
Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a new research.
International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK.
Scientists are carrying out clinical tests with patients who have suffered from a severe heart attack. With the implantation of the patient’s stem cells, the heart regenerates thus improving its wall motion, that is, its cardiac performance.
The immunosuppressive drugs required by organ transplant recipients after surgery can have serious side effects with prolonged use, including infection, heart disease and cancer. In an effort to reduce, or potentially eliminate the need for anti-rejection medications, researchers at Northwestern Memorial Hospital and Northwestern University’s Feinberg School of Medicine are investigating the efficacy of a stem cell transplant after organ transplant.
When evolution has lucked into efficient solutions for life’s most fundamental problems, it adopts them as invaluable family heirlooms, passing them down as one species evolves into another. So it was reasonable to expect that a key regulator of embryonic development — a strand of RNA that shepherds stem cells through the process of differentiation — might play the same role in all vertebrates, from fish to people. New research, however, has shown that when it comes to microRNAs, what works for one animal may not work the same way in another.
Bring It! participants include, in front row, James Pires, David Thomas, Ron Lack, Mary Macie and, back row, Andrew Morse, John Garrigan, Dawn Saunders and Chris High. Photos courtesy of Melissa Jacobs More than 300 people showed up in “game show elegant” attire for Bring It!, and raised about $150,000 for stem cell research in an event hosted by the Head North Foundation and the Burnham …
The technology for versatile, grow-in-a-dish transplant tissue took a step toward clinical use Thursday when researchers announced they have found a safe way to turn skin cells into stem cells.
StemCyte, Inc., a privately held cord blood bank and stem cell therapeutics company, recently released their 1,000th cord blood stem cell shipment for transplant. This marks another landmark in the company’s rapid growth as one of the world’s leading providers of quality, prescription cord blood stem cell product.
CALGARY, ALBERTA–(Marketwire – May 28, 2009) – Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (”SCT” or “the Company”) announces the acceptance and publication of a paper describing the effectiveness of the NTx(R)-265 stroke treatment regimen when administered 24 hours after an ischemic stroke in rats. For the first time, this therapeutic strategy was shown to improve behavioral outcome and …